KDventures AB Share Price

KDV B

SE0002190926

Investment Management & Fund Operators

Market Closed - Nasdaq Stockholm 09:30:00 19/10/2026 pm IST			5-day change	1st Jan Change
0.2545 ^SEK	0.00%		-0.97%	-41.63%

16/10	KDventures Chief Scientific Officer Steps Down	MT
15/10	John Öhd continues as senior adviser to KD Ventures	FW

Analysts' recommendations: KDventures AB

11/05	Redeye: KD Ventures trading at a steep discount to NAV	FW
11/05	Redeye initiates coverage of KD Ventures with a fair value of SEK 1.0 per share	FW
17/11	DNB Carnegie Lowers Target Value for Karolinska Development to SEK 1.4-2.1 per Share	FW
04/11	Karolinska Development's Modus Therapeutics gets approval for 2nd part of phase 2 study	RE
04/11	Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemia	CI

More recommendations

Managers and Directors: KDventures AB

Manager	Title	Age	Since
Viktor Drvota CEO	Chief Executive Officer	61	01/06/2017
Hans Christopher Toll DFI	Director of Finance/CFO	58	01/10/2022
Mikaela Sörman CIO	Chief Investment Officer	-	-

Director	Title	Age	Since
Theresa Y. Y. Tse BRD	Director/Board Member	33	28/11/2017
Anna Lefevre Skjöldebrand BRD	Director/Board Member	57	19/02/2021
Benjamin Toogood CHM	Chairman	50	18/12/2024

More insiders

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, womenâ€™s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Companyâ€™s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Employees

Sector

Investment Management & Fund Operators

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
19/26/19	SEK 0.2545	0.00%	44,868
16/26/16	SEK 0.2545	+8.53%	16,15,243
15/26/15	SEK 0.2345	-8.58%	32,84,338
14/26/14	SEK 0.2565	+2.40%	2,91,554
13/26/13	SEK 0.2505	-2.53%	11,75,115

Delayed Quote Nasdaq Stockholm

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - KDventures AB

Company calendar

Market Cap	19Cr 1.95Cr 1.74Cr 1.61Cr 1.46Cr 2.75Cr 184.86Cr 2.79Cr 7.59Cr 97Cr 7.32Cr 7.16Cr 308.87Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	19Cr 1.95Cr 1.74Cr 1.61Cr 1.46Cr 2.75Cr 184.86Cr 2.79Cr 7.59Cr 97Cr 7.32Cr 7.16Cr 308.87Cr	EV / Sales 2026 *	-0.41x	EV / Sales 2027 *	2.87x
Free-Float	52.57%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	KDV B	Delayed
CBOE	0P3C	Real-time
Deutsche Boerse AG	2I9	Delayed
CBOE	KDEVs	Real-time
Börse Stuttgart	2I9	Delayed
Boerse Muenchen	2I9	Real-time

16/10	KDventures Chief Scientific Officer Steps Down	MT
15/10	John Öhd continues as senior adviser to KD Ventures	FW
15/10	KDventures AB Announces Transition of John Öhd from Chief Scientific Officer to Senior Advisor	CI
15/10	KD Ventures portfolio company pauses enrollment in phase 2a trial	FW
30/09	KD Ventures halves value of its holding in Anacardio	FW
15/09	KD Ventures: Umecrine completes patient phase in PBC study	FW
07/09	Block trade of 0.6 percent of the capital executed in KD Ventures	FW
07/09	KD Ventures portfolio company Umecrine Cognition receives two patent approvals in the US	FW
04/09	KD Ventures portfolio company Modus Therapeutics carries out a directed share issue	FW
28/08	KDventures AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
28/08	KD Ventures reports lower net asset value	FW
03/08	Umecrine Cognition has enrolled the last patient in study	FW
09/07	KD Ventures portfolio company PharmNovo raises SEK 39m	FW

07/10	KDventures : portfolio company Umecrine Cognition invited to showcase Parkinson's disease program and new translational data at The Michael J. Fox Foundation's PDTC 2026	PU
07/10	KDventures portfolio company Umecrine Cognition invited to showcase Parkinson’s disease program and new translational data at The Michael J. Fox Foundation’s PDTC 2026	AQ
30/09	KDventures' : portfolio company AnaCardio raises EUR 62.5 million in Series B financing	PU
30/09	KDventures’ portfolio company AnaCardio raises EUR 62.5 million in Series B financing	AQ
15/09	KDventures : rsquo; portfolio company Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis	PU

1 week	-0.97%
Current month	-2.30%
1 month	-8.78%
3 months	+3.67%
6 months	-0.78%
Current year	-41.63%

KDventures AB Share Price

Stocks

KDV B

SE0002190926

Investment Management & Fund Operators

Valuation: KDventures AB

Chart: KDventures AB

Latest news: KDventures AB

Analysts' recommendations: KDventures AB

Press Releases: KDventures AB

Quotes and Performance

Price Extremes

Managers and Directors: KDventures AB

Latest insider transactions

Private Equity

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	0.23	0.26
1 month	0.23	0.28
Current year	0.2	0.45
1 year	0.2	0.89
3 years	0.2	1.95
5 years	0.2	11.24
10 years	0.2	11.24

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/03/23	Johan Dighed	Buy	General Counsel	50,000	0.0187%
30/09/22	Johan Dighed	Buy	General Counsel	40,187	0.0150%
08/03/22	Benjamin Toogood	Buy	Chairman	64,001	0.0367%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KDVENTURES AB	0.00%	-0.97%	-70.75%	-83.50%	1.95Cr
BLACKROCK, INC.	-0.86%	+3.75%	-3.15%	+80.66%	17TCr
UBS GROUP AG	-1.39%	-2.32%	+29.06%	+80.01%	14TCr
BANK OF NEW YORK MELLON CORPORATION (THE)	-0.60%	-0.29%	+34.40%	+237.62%	9.58TCr
BLACKSTONE INC.	+0.45%	-6.70%	-31.49%	+13.66%	8.57TCr
BROOKFIELD CORPORATION	-0.60%	-2.81%	-17.33%	+80.35%	8.15TCr
KKR & CO. INC.	+0.92%	-4.93%	-26.02%	+56.45%	7.81TCr
BROOKFIELD ASSET MANAGEMENT LTD.	-0.44%	-2.69%	-16.02%	+51.23%	7.23TCr
APOLLO GLOBAL MANAGEMENT, INC.	+0.15%	-6.94%	-8.59%	+33.07%	6.55TCr
STATE STREET CORPORATION	-0.17%	-5.43%	+48.54%	+149.29%	4.51TCr
Average	-0.25%	-2.55%	-6.13%	+69.88%	8.43TCr
Weighted average by Cap.	-0.45%	-1.80%	+1.53%	+86.76%

	2026 *	2027 *
Net sales	-48Cr -4.81Cr -4.29Cr -3.97Cr -3.61Cr -6.78Cr -456.04Cr -6.89Cr -19Cr -238.35Cr -18Cr -18Cr -761.96Cr	6.74Cr 68.05L 60.66L 56.19L 51.09L 95.87L 65Cr 97.45L 2.65Cr 34Cr 2.55Cr 2.5Cr 107.8Cr
Net income	-50Cr -5.02Cr -4.47Cr -4.14Cr -3.77Cr -7.07Cr -475.67Cr -7.18Cr -20Cr -248.61Cr -19Cr -18Cr -794.74Cr	4.54Cr 45.84L 40.86L 37.85L 34.42L 64.58L 43Cr 65.64L 1.79Cr 23Cr 1.72Cr 1.68Cr 73Cr
Net Debt	-	-